Concurrent autoimmune hepatitis in multiple sclerosis

2017 ◽  
Vol 24 (3) ◽  
pp. 350-353 ◽  
Author(s):  
Gonçalo Cação ◽  
Ernestina Santos ◽  
Ana Martins Silva
Keyword(s):  
Multiple Sclerosis ◽  
Liver Biopsy ◽  
Autoimmune Hepatitis ◽  
Interferon Beta ◽  
Immunosuppressive Treatment ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Rare Association ◽  
Disease Modifying Therapy ◽  
Disease Modifying

Background: Autoimmune hepatitis (AIH) is a rare and chronic inflammatory disorder associated with extrahepatic autoimmune diseases, including, infrequently, multiple sclerosis (MS). Short Reports: We report five cases of MS and AIH association. One patient developed AIH while under interferon beta-1b and the remaining while off disease-modifying therapy, although after methylprednisolone bolus in three. All presented a liver biopsy compatible with AIH. Hepatitis resolution was achieved with immunosuppressive treatment, but one patient died after a fulminant hepatitis requiring liver transplant. Discussion: A thorough review of published cases supports this clear, although rare, association and a liver biopsy should be considered in AIH suspected cases.

Application of Interferon Beta-1b in Multiple Sclerosis

US Neurology ◽  
2011 ◽  
Vol 07 (01) ◽  
pp. 46 ◽  
Author(s):  
Francesca Bagnato ◽  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Interferon Beta ◽  
Regulatory Agencies ◽  
Recombinant Interferon ◽  
Beneficial Effects ◽  
Disease Modifying Therapy ◽  
The World ◽  
Disease Modifying ◽  
Inflammatory Component

Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical and imaging measures of disease. Upon only briefly discussing the side effects of the drug, it will conclude with some crucial scientific aspects warranting urgent investigations to precisely address the potentials of IFNβ-1b in MS patients.

scholarly journals Application of Interferon Beta-1b in Multiple Sclerosis

2011 ◽  
Vol 6 (1) ◽  
pp. 36 ◽  
Author(s):  
Francesca Bagnato ◽  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Interferon Beta ◽  
Regulatory Agencies ◽  
Recombinant Interferon ◽  
Beneficial Effects ◽  
Disease Modifying Therapy ◽  
The World ◽  
Disease Modifying ◽  
Inflammatory Component

Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical and imaging measures of disease. Upon only briefly discussing the side effects of the drug, it will conclude with some crucial scientific aspects warranting urgent investigations to precisely address the potentials of IFNβ-1b in MS patients.

COVID-19 in two patients with multiple sclerosis treated with beta interferons

2021 ◽  
Vol 36 (4) ◽  
pp. 327-334
Author(s):  
Karolina Kania ◽  
Elżbieta Tokarz-Kupczyk ◽  
Alicja Kalinowska-Łyszczarz
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Medical Literature ◽  
Case Reports ◽  
Published Data ◽  
Clinical Experiences ◽  
Disease Modifying Therapy ◽  
Increased Risk ◽  
Disease Modifying ◽  
Benign Course

Objectives. Treatment of multiple sclerosis (MS) in the era of the COVID-19 (coronavirus disease 2019) pandemic raises many questions for doctors. Case reports. We are presenting two cases of patients suffering from multiple sclerosis (MS) treated with interferon beta-1b and interferon beta-1a, who suffered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with a benign course in one case and an asymptomatic one in another. None of the patients required hospitalisation. Conclusions. MS treatment during coronavirus disease 2019 (COVID-19) pandemics poses several questions. Considering our own clinical experiences, we present a brief review of medical literature on the safety of MS immunotherapy. So far, the published data on MS and COVID-19 do not show increased risk associated with MS diagnosis or disease modifying therapy, even when associated with immunosuppression.

A Case of Intractable Vomiting

2018 ◽  
pp. 157-162
Author(s):  
Aaron E. Miller ◽  
Tracy M. DeAngelis ◽  
Michelle Fabian ◽  
Ilana Katz Sand
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Area Postrema ◽  
Inflammatory Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Clinical Imaging ◽  
Prompt Treatment ◽  
Disease Modifying Therapy ◽  
The Central Nervous System ◽  
Disease Modifying

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder affecting the central nervous system, with clinical, imaging, and laboratory characteristics that are distinct from multiple sclerosis. It presents most commonly with optic neuritis, myelitis, or an area postrema syndrome consisting of intractable nausea, vomiting, or hiccups. Most patients are positive for serum antibodies to aquaporin 4. Prompt treatment with corticosteroids and/or plasma exchange is critical for recovery, as is the initiation of disease-modifying therapy with an immunomodulatory agent to prevent future attacks. First-line disease-modifying therapies for NMOSD include rituximab, mycophenolate mofetil, and azathioprine. Several additional agents are used less commonly, and others are currently in clinical trials.

scholarly journals Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis

2019 ◽  
Author(s):  
Seyed Mohammad Baghbanian ◽  
Mohammad Ali Sahraian
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Immunomodulatory Agents ◽  
Disease Modifying Drugs ◽  
Disease Modifying Therapy ◽  
Immune Mediated ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Relapsing Remitting Multiple Sclerosis

Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice.

Sign in / Sign up

Export Citation Format

Share Document